Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Four British Columbia students awarded 2010 UCBeyond Scholarship

For four students from British Columbia, their stories of perseverance in pursuing their hopes and dreams despite their illnesses is why they have been awarded $5,000 CAN each as the 2010 recipients of the UCBeyond Scholarship.

13 Oct 2010

Researchers develop new approach to treat inflammatory bowel disease

Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases. Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but how to deliver them into targeted cells in a living organism has been an obstacle.

11 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Cincinnati Children's Hospital receives $12 million grant to create IBD registry

Building on the success of previous efforts among researchers and caregivers to improve the care of chronically ill children, a $12-million grant to Cincinnati Children's Hospital Medical Center will allow creation of a registry system unlike any before it, providing information in real time on thousands of cases around the country – and eventually the world.

7 Oct 2010

Fish oil induces severe colitis and colon cancer in mice

Fish oil - long encouraged by doctors as a supplement to support heart and joint health, among other benefits - induced severe colitis and colon cancer in mice in research led by Michigan State University and published this month in the journal Cancer Research.

6 Oct 2010

CEUS ultrasound offers superior efficacy to CT scans

Contrast-enhanced ultrasound (CEUS) can be used to evaluate and monitor inflammatory bowel disease (IBD) without exposing patients to CT scans or ionizing radiation, according to a report announced today (Friday) at the ICUS Bubble Conference in Chicago.

4 Oct 2010

Scientists find new replicating mechanism of Salmonella bacteria

New findings by National Institutes of Health scientists could explain how Salmonella bacteria, a common cause of food poisoning, efficiently spread in people. In a study published this week in the Proceedings of the National Academy of Sciences, researchers describe finding a reservoir of rapidly replicating Salmonella inside epithelial cells. These bacteria are primed to infect other cells and are pushed from the epithelial layer by a new mechanism that frees the Salmonella to infect other cells or be shed into the intestine.

3 Oct 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

Global Health Partner acquires Stockholm Gastro Center

Global Health Partner (STO:GHP) has acquired Stockholm Gastro Center, a specialist clinic with operations within medical gastroenterology and endoscopy located at Sophiahemmet in Stockholm. "The acquisition of Stockholm Gastro Center is a good complement to the obesity surgery business that we run at Kirurgkliniken and Bariatric Center Stockholm in Sophiahemmet's facilities. This is a combination of businesses that we also have at our clinics in Lund and Prague and where we see good coordination and expansion opportunities," says Per Båtelson, Global Health Partner's CEO.

28 Sep 2010

BioSeek signs two-year agreement with Cellzome

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a two-year agreement with Cellzome.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Phenex Pharmaceuticals announces closure of Series C financing round

Phenex Pharmaceuticals AG, a drug discovery and development company headquartered in Ludwigshafen, Germany, today announced the closure of its Series C financing round with a volume of 6 M € (7,8 M USD) bringing the total amount of funds raised to 17,2 M € (22,4 M USD).

21 Sep 2010

FDA grants orphan drug designation for MultiStem stem cell therapy

Athersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell therapy, has been granted orphan drug designation by the U. S. Food and Drug Administration for the prevention of graft vs. host disease (GvHD).

21 Sep 2010

Pollution increases risk for sudden cardiac arrest

The fine particles of pollution that hang in the air can increase the risk for sudden cardiac arrest, according to a new study conducted by a team from Long Island Jewish (LIJ) Medical Center and The Feinstein Institute for Medical Research.

21 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia, Humira and Remicade utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

17 Sep 2010

Researchers identify bacteria responsible for chronic intestinal inflammation

Certain bacteria that inhabit the intestine provide the environmental trigger that initiates and perpetuates chronic intestinal inflammation in individuals who are genetically susceptible to inflammatory bowel disease (IBD), a study led by Harvard School of Public Health researchers has found.

17 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010